Duke University's Center For Human Genetics Selects Illumina, Inc.'s Infinium HumanHap550 BeadChip For Landmark Autism Study

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) announced today that Duke University’s Center for Human Genetics (CHG) has selected the Infinium HumanHap550 BeadChip for an Autism study of over 1,800 individuals and their families. The identification of the genes which contribute to complex disease like autism will lead to the development of enhanced diagnostic tools, early detection, and improved health outcomes for patients and their families. Autism is a disease that affects 10 to 20 of every 10,000 people and is expected to affect 4 million people by the end of the decade.

Back to news